Trump threatens India for Malaria medicine

Trump threatens India for Malaria medicine

#Trump warns retaliation

#Demands anti-Malaria drug export from India

#India last week banned anti Malaria drug

#Malaria Drug export likely to reopen today

The US President Donald Trump literally threatened India of retaliation if the anti Malaria medicine India mass produce are not given to the US to fight Corona Virus.

"I would be surprised if he would, you know because India does very well with the United States," Mr. Trump told reporters during a press briefing at the White House on Monday.

"So, I would be surprised if that were his (Prime Minister Narendra Modi's) decision. He'd have to tell me that. I spoke to him Sunday morning, called him, and I said we'd appreciate your allowing our supply to come out. If he doesn't allow it to come out, that would be okay, but of course, there may be retaliation. Why wouldn't there be?" the US President was quoted as saying by the news agency.

Meanwhile, amid rising pressure to allow exports of an anti-malarial drug being tested on patients infected with coronavirus, the government is likely to make a decision today and clear the move after calculating sufficient stocks for the country.

Last month, India had banned the export ofhydroxychloroquine and formulations of the malaria drug while experts test itsefficacy in helping treat COVID-19 patients.

There are currently no approved treatments or preventive vaccines for COVID-19 but Hydroxychloroquine, a malaria drug, is among the medications undergoing testing as a potential treatment for patients with the disease. India is one of the world's largest manufacturers of medicine.

Meanwhile, the Union Health Ministry  said  that there is not sufficient evidence to use  this medicine it at the community level

There is limited evidence on the efficacy ofhydroxychloroquine to deal with COVID-19 and there is not enough evidence proofto advise it for people, the Ministry of Health and Family Welfare JointSecretary, Lal Aggarwal said on Monday.

"We have allowed the use of Hydroxychloroquine forhealthcare workers dealing with COVID-19 patients or high-risk contacts of thepatients though there is limited evidence of its efficacy. There is notsufficient evidence to use it at the community level," Aggarwal said in apress conference.

"We have issued advisory related to it. Every medicinehas side effects. Because we have allowed it based on limited evidence in somelocations, there is a misconception that anyone can take it. We should followtechnical guidance. Those who are not advised to take this medicine should nottake it," he said.

The Union Health Ministry had earlier placed an order ofabout 10 crore hydroxychloroquine tablets with various pharmaceutical companiesfor healthcare workers.

The Indian Council of Medical Research (ICMR) has suggestedthe use of hydroxychloroquine tablets only for healthcare workers andcaregivers involved in the treatment and in direct contact with suspected orconfirmed COVID-19 patients.

Related Stories

No stories found.

No stories found.
Pratidin Time